IDH2 and cholangiocarcinoma: Similarly, a phase II study of olaparib and durvalumab in IDH-mutated CCA was discontinued after stage I due to lack of efficacy (no complete or partial responses; mPFS: 1.97 months) (Supplementary Table S1) [134].